BACKGROUND: Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized. METHODS: We measured HIV-1 RNA in cervical swab specimens obtained from participants in the Women's Interagency HIV Study who had concurrent plasma viral RNA levels <500 copies/mL, and we assessed factors associated with genital HIV shedding. The study was powered to determine the relative effects of antiretroviral protease inhibitors (PIs) versus nonnucleoside reverse transcriptase inhibitors (NNRTIs) on viral RNA shedding. RESULTS: Overall, 44 (15%) of 290 women had detectable HIV-1 RNA in cervical specimens. In the final multivariate model, shedding was independently associated with NNRTI (vs. PI) use (odds ratio [OR], 95% confidence interval [CI]: 2.24, 1.13 to 4.45) and illicit drug use (OR, 95% CI: 2.41, 0.96 to 5.69). CONCLUSIONS: This is the largest study to define risks for genital HIV-1 RNA shedding in women with low/undetectable plasma virus. Shedding in this population was common, and NNRTI-based highly active antiretroviral therapy (HAART) (vs. PI-based HAART) was associated with genital HIV shedding. Further study is required to determine the impact of these findings on transmission of HIV from mother to child or to sexual partners.
BACKGROUND: Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized. METHODS: We measured HIV-1 RNA in cervical swab specimens obtained from participants in the Women's Interagency HIV Study who had concurrent plasma viral RNA levels <500 copies/mL, and we assessed factors associated with genital HIV shedding. The study was powered to determine the relative effects of antiretroviral protease inhibitors (PIs) versus nonnucleoside reverse transcriptase inhibitors (NNRTIs) on viral RNA shedding. RESULTS: Overall, 44 (15%) of 290 women had detectable HIV-1 RNA in cervical specimens. In the final multivariate model, shedding was independently associated with NNRTI (vs. PI) use (odds ratio [OR], 95% confidence interval [CI]: 2.24, 1.13 to 4.45) and illicit drug use (OR, 95% CI: 2.41, 0.96 to 5.69). CONCLUSIONS: This is the largest study to define risks for genital HIV-1 RNA shedding in women with low/undetectable plasma virus. Shedding in this population was common, and NNRTI-based highly active antiretroviral therapy (HAART) (vs. PI-based HAART) was associated with genital HIV shedding. Further study is required to determine the impact of these findings on transmission of HIV from mother to child or to sexual partners.
Authors: Sherene S Min; Amanda H Corbett; Naser Rezk; Susan Cu-Uvin; Susan A Fiscus; Leslie Petch; Myron S Cohen; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: A Kovacs; S S Wasserman; D Burns; D J Wright; J Cohn; A Landay; K Weber; M Cohen; A Levine; H Minkoff; P Miotti; J Palefsky; M Young; P Reichelderfer Journal: Lancet Date: 2001-11-10 Impact factor: 79.321
Authors: Y Cao; P Krogstad; B T Korber; R A Koup; M Muldoon; C Macken; J L Song; Z Jin; J Q Zhao; S Clapp; I S Chen; D D Ho; A J Ammann Journal: Nat Med Date: 1997-05 Impact factor: 53.440
Authors: L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: C E Hart; J L Lennox; M Pratt-Palmore; T C Wright; R F Schinazi; T Evans-Strickfaden; T J Bush; C Schnell; L J Conley; K A Clancy; T V Ellerbrock Journal: J Infect Dis Date: 1999-04 Impact factor: 5.226
Authors: Kimdar Sherefa Kemal; Brian Foley; Harold Burger; Kathryn Anastos; Howard Minkoff; Christina Kitchen; Sean M Philpott; Wei Gao; Esther Robison; Susan Holman; Carolyn Dehner; Suzanne Beck; William A Meyer; Alan Landay; Andrea Kovacs; James Bremer; Barbara Weiser Journal: Proc Natl Acad Sci U S A Date: 2003-10-13 Impact factor: 11.205
Authors: S García-Bujalance; G Ruiz; C Ladrón De Guevara; J M Peña; I Bates; J J Vázquez; A Gutiérrez Journal: Eur J Clin Microbiol Infect Dis Date: 2004-01-20 Impact factor: 3.267
Authors: Josè Ramòn Fiore; Barbara Suligoi; Annalisa Saracino; Mariantonietta Di Stefano; Roberto Bugarini; Achiropita Lepera; Anna Favia; Laura Monno; Gioacchino Angarano; Giuseppe Pastore Journal: AIDS Date: 2003-10-17 Impact factor: 4.177
Authors: Caroline Mitchell; Jane Hitti; Kathleen Paul; Kathy Agnew; Susan E Cohn; Amneris E Luque; Robert Coombs Journal: AIDS Res Hum Retroviruses Date: 2010-10-07 Impact factor: 2.205
Authors: Ruth W Gitau; Susan M Graham; Linnet N Masese; Julie Overbaugh; Vrasha Chohan; Norbert Peshu; Barbra A Richardson; Walter Jaoko; Jeckoniah O Ndinya-Achola; R Scott McClelland Journal: AIDS Date: 2010-11-13 Impact factor: 4.177
Authors: Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Kartik K Venkatesh; Allison K DeLong; Rami Kantor; Stacey Chapman; Jessica Ingersoll; Jaclynn Kurpewski; Maria Pia De Pasquale; Richard D'Aquila; Angela M Caliendo; Susan Cu-Uvin Journal: J Womens Health (Larchmt) Date: 2013-03-26 Impact factor: 2.681
Authors: Megan Justine Huchko; Victoria Woo; Teri Liegler; Anna Leddy; Karen Smith-McCune; George F Sawaya; Elizabeth A Bukusi; Craig R Cohen Journal: J Low Genit Tract Dis Date: 2013-07 Impact factor: 1.925